Log In
Print
BCIQ
Print
Print this Print this
 

elotuzumab (BMS-901608, HuLuc63) (formerly PDL 063)

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionHumanized mAb targeting cell-surface glycoprotein CS1
Molecular Target Cell-surface glycoprotein CS1
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed or refractory multiple myeloma (MM)
Regulatory Designation

Switzerland - Orphan Drug (Treat multiple myeloma (MM))

Partner

Bristol-Myers Squibb Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today